Third-quarter earnings take hit on failure of inhaled-insulin drug
(Newser) -
The world's largest drug maker took a 77% hit in third-quarter net income after dropping Exubera, its inhaled insulin product. Competition from generic drugs also pulled down sales, Pfizer announced this morning, as the company lowered its 2007 net-income forecast.
More »
